LIZHI WANG¹, HUILIN SUN², GUIZHI YU¹, ZEJING QU¹, YING JI¹, YANPING CUI^1,*

Oncology Research, Vol.33, No.4, pp. 885-894, 2025, DOI:10.32604/or.2024.051586 - 19 March 2025

Abstract Background: Small cell lung cancer (SCLC) is characterized by its aggressive nature and high propensity for brain metastases. This study investigates the clinical efficacy and safety profile of Anlotinib in combination with Stereotactic Radiotherapy (SRT) for treating brain metastases in patients with small cell lung cancer (SCLC). Methods: This research included 98 SCLC brain metastasis patients treated at Chengde Central Hospital from October 2020 to January 2024. The patients were categorized into a combined treatment group (CTG) (n = 45) and a Simple SRT group (SSG)(n = 53). The CTG (58 lesions) received Anlotinib with… More >

ENRICO CALIMAN^1,2, SARA FANCELLI^1,2, FEDERICO SCOLARI³, ADRIANO PASQUI⁴, CLARA MANNESCHI⁴, DANIELE LAVACCHI¹, FRANCESCA MAZZONI⁴, FRANCESCA GENSINI⁵, VALERIA PASINI⁶, CAMILLA EVA COMIN^2,7, LUCA VOLTOLINI^2,8, SERENA PILLOZZI^1,2,*, LORENZO ANTONUZZO^1,2,4

Oncology Research, Vol.33, No.1, pp. 45-55, 2025, DOI:10.32604/or.2024.050161 - 20 December 2024

Abstract Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients’ survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes—namely ERCC1, ERCC2,… More >

SHIQIN JIANG^1,#, YICHUN TANG^2,#, FENG MA³, YUCHUN NIU^4,*, LEI SUN^5,*

Oncology Research, Vol.33, No.1, pp. 213-224, 2025, DOI:10.32604/or.2024.046895 - 20 December 2024

Abstract Objective: Small cell lung cancer (SCLC) is commonly recognized as the most fatal lung cancer type. Despite substantial advances in immune checkpoint blockade therapies for treating solid cancers, their benefits are limited to a minority of patients with SCLC. In the present study, novel indicators for predicting the outcomes and molecular targets for SCLC treatment were elucidated. Methods: We conducted bioinformatics analysis to identify the key genes associated with tumor-infiltrating lymphocytes in SCLC. The functional role of the key gene identified in SCLC was determined both in vitro and in vivo. Results: A significant correlation was observed between… More >

Hailin Pang¹, Ningqiang Ma¹, Mi Jiao, Weiwei Shen, Bo Xin, Tongfei Wang, Feng Zhang, Lili Liu, Helong Zhang

Oncology Research, Vol.25, No.1, pp. 35-42, 2017, DOI:10.3727/096504016X14719078133249

Abstract The bone is among the most common sites of metastasis in patients with lung cancer. Over 30%–40% of lung cancers can develop bone metastasis, and no effective therapeutic methods exist in clinic cases. Wnt/β-catenin signaling and Dickkopf1 (DKK1) play important roles in the progression of lung cancer, which preferentially metastasizes to the skeleton. However, the role of DKK1 in osteotropism of small cell lung cancer (SCLC) remains to be elucidated. This study aimed to define the role of DKK1 in SCLC bone metastasis and investigate the underlying mechanisms. Our results demonstrated that the expression level… More >